

1 **Manuscript Title:**

2 **Coinfection with Respiratory Pathogens in COVID-19 in Korea**

3 **Running title:** Coinfection in COVID-19

4 Kyoung Ho Roh<sup>a\*</sup>, Yu Kyung Kim<sup>b\*</sup>, Shin-Woo Kim<sup>c</sup>, Eun-Rim Kang<sup>a</sup>, Yong-Jin Yang<sup>a</sup>,  
5 Sun-Kyung Jung<sup>a</sup>, Sun-Hwa Lee<sup>a</sup>, Nackmoon Sung<sup>a\*\*</sup>

6

7 <sup>a</sup>Clinical Research Institute/Molecular Diagnosis Center, Seegene Medical Foundation,  
8 Seoul, Rep. of Korea

9 <sup>b</sup>Department of Clinical Pathology, School of Medicine, Kyungpook National University  
10 Hospital, Daegu, Rep. of Korea

11 <sup>c</sup>Division of Infectious Disease, Department of Internal Medicine, Kyungpook National  
12 University Hospital, Daegu, Rep. of Korea

13 \* K. H. Roh and Y. K. Kim: equally contributed

14 **\*\*Corresponding author:** Nackmoon Sung, Ph.D.

15 Clinical Research Institute/Molecular Diagnosis Center

16 320 Cheonho-Daero, Seongdong-gu, Seoul, 04805, Rep. of Korea

17 E-mail: [paratb@gmail.com](mailto:paratb@gmail.com).

18 <sup>+</sup> Present Address of K. H. Roh: Department of Laboratory Medicine, National Health

19 Insurance Service Ilsan Hospital, Goyang, Gyeonggo, Rep. of Korea

20

## 21 **AUTHOR CONTRIBUTION**

22 Conception and design: K. H. Roh, Y. Kim, S-W Kim, N. Sung; Acquisition of data: E.

23 Kang, Y-J Yang, S. Jung, S-H Lee; Data analysis and interpretation: E. Kang, Y-J Yang,

24 K.H. Roh, Y. Kim, N. Sung; Drafting of the manuscript: K.R. Roh, Y. Kim, S-W Kim, N.

25 Sung; Critical revision of the manuscript: K. H. Roh, Y. Kim, S-W Kim, N. Sung; Approval

26 of final manuscript: all authors

27

## 28 **ORCID**

29 K.H. Roh: <http://orcid.org/0000-0002-6291-9229>

30 Y.K. Kim: <https://orcid.org/0000-0002-4699-8502>

31 S-W. Kim: <http://orcid.org/0000-0002-3755-8249>

32 E-R. Kang: <https://orcid.org/0000-0003-1677-9883>

33 Y-J. Yang: <https://orcid.org/0000-0002-6153-9646>

34 S-K. Jung: <https://orcid.org/0000-0002-1450-8150>

35 S-H. Lee: <https://orcid.org/0000-0002-6393-4500>

36 N. Sung: <http://orcid.org/0000-0001-8951-163X>

## 37 **Abstract**

38           Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in  
39 upper and lower respiratory specimens and coinfection with other respiratory pathogens  
40 in patients with coronavirus disease 2019 (COVID-19) were investigated. From the study  
41 subjects (N = 258) retrospectively enrolled when confirmed as SARS-CoV-2 positive,  
42 nasopharyngeal (NPS), oropharyngeal swabs (OPS), and sputum specimens were  
43 restored for retesting SARS-CoV-2 and detecting respiratory pathogens. Majority of the  
44 study subjects (95.7%, N = 247) were confirmed as SARS-CoV-2 positive using NPS/OPS  
45 specimens, suggesting that the upper respiratory specimen is most valuable in detecting  
46 SARS-CoV-2. Coinfection rates in COVID-19 patients (N = 258) with respiratory  
47 pathogens were 9.7% (N = 25); 8.5% (N = 22) respiratory viruses and 1.2% (N = 3)  
48 *Mycoplasma pneumoniae*, an atypical bacterium. Of the respiratory virus coinfection  
49 cases (N = 22), 20 (90.9%) were co-infected with a single respiratory virus and 2 (0.8%)  
50 (metapneumovirus/adenovirus and rhinovirus/bocavirus 1/2/3/4) with two viruses.  
51 Respiratory viruses in single viral coinfection cases with SARS-CoV-2 were as follows:  
52 non-SARS-CoV-2 coronaviruses (229E, NL63, and OC43, N = 5, 1.9%), rhinovirus (N =  
53 4, 1.6%), metapneumovirus (N = 3, 1.2%), influenza A (N = 3, 1.2%), respiratory syncytial  
54 virus A and B (N = 3, 1.2%), and adenovirus (N = 2, 0.8%). No mixed coinfections with  
55 respiratory viruses and *M. pneumoniae* were found. In conclusion, the diagnostic value  
56 of utilizing NPS/OPS specimen is excellent, and, as the first report in Korea, coinfection  
57 with respiratory pathogens were detected at a rate of 9.7% in patients with COVID-19.

58 **Key Words:** COVID-19, Coinfection, Respiratory Pathogens, Influenza

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

## 75 **Introduction**

76 COVID-19, caused by the infection of SARS-CoV-2, was identified as a cluster of  
77 pneumonia cases in Wuhan, China, in December 2019, and has spread to other countries  
78 since then, resulting in 42 million cases and over 1.1 million deaths globally as of October  
79 25, 2020 (1).

80 In Korea, a Chinese female from Wuhan, China, was identified as the first COVID-  
81 19 case on January 19, 2020, during the quarantine inspection at Incheon airport (2).  
82 Suspects with respiratory symptoms and/or a history of travel to other countries, including  
83 China, were asked to test for SARS-CoV-2 infection, causing exponential growth by  
84 conducting real-time PCR (RT-PCR) tests to identify COVID-19 using emergency use  
85 authorized (EUA) *in vitro* diagnostics (IVD) assays (3).

86 For the fast and accurate diagnosis of SARS-CoV-2 using IVD assays, the  
87 selection of appropriate types of specimens collected from patients at the right time would  
88 be an important factor (4). It has been reported that lower respiratory specimens such as  
89 bronchoalveolar lavage fluid and sputum have been recommended as the best clinical  
90 respiratory specimens for detecting SARS-CoV-2 (5, 6). Viral loads of SARS-CoV-2 were  
91 higher in nasal swabs than those in throat swabs collected from symptomatic COVID-19  
92 patients (7). The Centers for Disease Control and Prevention recommended upper  
93 respiratory specimens as acceptable for initial diagnostic testing of SARS-CoV-2 in the  
94 types of nasopharyngeal swab (NPS), oropharyngeal swab (OPS), nasal swab, and saliva  
95 (8). Simultaneous collection and placement of NPS and OPS in a universal transport

96 medium (UTM) tube using two sets of swabs is recommended to increase sensitivity in  
97 real-time polymerase chain reaction (RT-PCR) assays in Korea, as long as the supply of  
98 flocked swabs is not limited (9). We analyzed the number of patients with COVID-19 that  
99 were confirmed as positive using NPS/OPS by measuring the detection rates of SARS-  
100 COV-2 among the patients diagnosed during the screening process in the first outbreak  
101 of the disease in Korea.

102 The IVD assays for detecting SARS-CoV-2 were not incorporated for testing  
103 coinfections with other respiratory pathogens at the time of screening COVID-19 suspects.  
104 Recently, coinfections in COVID-19 have been reported not to neglect infections by other  
105 respiratory pathogens in addition to SARS-CoV-2 (10-14). This suggests that  
106 simultaneous testing for coinfections between SARS-CoV-2 and other respiratory  
107 pathogens would be required to provide a better patient treatment during the COVID-19  
108 pandemic (15).

109 Among the respiratory pathogens, including tuberculosis, virus and bacteria have  
110 been predominantly reported as coinfection agents in COVID-19, as seen in the previous  
111 influenza pandemic (10, 12, 16, 17). Common coinfecting viruses with SARS-CoV-2  
112 include respiratory syncytial virus, influenza, rhinovirus/enterovirus, parainfluenza,  
113 metapneumovirus, and non-SARS-CoV-2 coronaviruses, and the coinfecting bacteria  
114 included *Mycoplasma pneumoniae*, *Legionella pneumophila*, *Chlamydia pneumoniae*,  
115 *Pseudomonas aeruginosa*, *Haemophilus influenzae*, and *Streptococcus pneumoniae*  
116 (10-13).

117           In this study, we simultaneously detected frequently reported respiratory viruses  
118 and atypical bacteria in clinical specimens collected from patients with COVID-19 to  
119 identify coinfection rates using RT-PCR-based commercial assays. Upper (NPS and OPS)  
120 and lower (sputum) respiratory tract specimens were employed to investigate the  
121 coinfections with respiratory pathogens when COVID-19 was confirmed as positive during  
122 the screening process.

123           This study reports simultaneous detection of SARS-CoV-2 and coinfection with  
124 respiratory pathogens (viruses and atypical bacteria) using commercially available RT-  
125 PCR assays among COVID-19 patients confirmed during the first outbreak in Korea.

126

127

128

129

130

131

132

133

134

135

## 136 **Materials and Methods**

### 137 **Study subjects**

138 Request forms of COVID-19 suspects submitted to Seegene Medical Foundation,  
139 a Non-Profit Independent Clinical Reference Laboratory, for detecting SARS-CoV-2 from  
140 February 9 to 23, 2020, were retrospectively reviewed. The request forms were generated  
141 and recorded by government healthcare centers, hospitals, or quarantine offices with  
142 personal and clinical information of COVID-19 suspects, such as name, address, age,  
143 birth date, sex, specimen type and collection date, and respiratory symptoms including  
144 history of visiting foreign countries, based on the guidelines of the Korea Disease Control  
145 and Prevention Agency (KDCA). Once request forms with respiratory tract specimens  
146 (NPS/OPS and/or sputum) collected from the suspects were submitted, the test results  
147 were reported within 24 h of turnaround time. Based on the guidelines for testing COVID-  
148 19 in Korea, both upper respiratory tract samples (NPS and OPS) were placed in a tube  
149 containing a UTM to increase test sensitivity (9, 18, 19).

150 We reviewed the request forms and enrolled study subjects who were COVID-19  
151 positive for fever ( $> 37.5^{\circ}\text{C}$ ) and cough because these two respiratory symptoms were  
152 reported as the most common (10, 16). The respiratory specimens (UTM containing  
153 NPS/OPS as upper respiratory specimen and sputum as lower respiratory specimen) of  
154 the study subjects were restored from storage freezers ( $-70^{\circ}\text{C}$ ) and applied to extract  
155 nucleic acids to reconfirm SARS-CoV-2 and detect respiratory pathogens simultaneously.

156



## 157 **Specimen preparation and nucleic acid extraction**

158           Specimens collected from the enrolled study subjects were subjected to nucleic  
159 acid extraction as described below for detecting SARS-CoV-2 and respiratory pathogens.  
160 A portion (200  $\mu$ L) of the UTM containing NPS/OPS was directly applied to the nucleic  
161 acid extraction. The sputum specimens were inspected for viscosity, homogenized, and  
162 diluted with phosphate-buffered saline as recommended by the specimen treatment  
163 guidelines of the Korean Society for Laboratory Medicine (9, 18) Then, 200  $\mu$ L of diluted  
164 sputum was applied for nucleic acid extraction.

165           Nucleic acid extraction was carried out by mixing the specimen (UTM or diluted  
166 sputum) and ready-to use reagents of a commercial kit (MagNA Pure 96 DNA and Viral  
167 NA Small Volume Kit; Roche Applied Diagnostics, Mannheim, Germany) as  
168 recommended by the manufacturer. The mixtures were placed in MagNA Pure 96  
169 instruments (Roche Diagnostics) and processed for nucleic acid extraction according to  
170 the manufacturer's instructions. The final elution volume of nucleic acids extracted from  
171 each specimen was approximately 100  $\mu$ L. The extracted nucleic acids were stored at -  
172 70°C and used for detecting SARS-CoV-2 and respiratory pathogens.

173

## 174 **Detection of SARS-CoV-2 and respiratory pathogens using RT-PCR**

175           To detect SARS-CoV-2, a commercial RT-PCR assay (Allplex™ 2019-nCoV Assay,  
176 Seegene Inc., Seoul, Republic of Korea) was employed in this study. Briefly, the extracted

177 nucleic acids (8  $\mu$ L) were mixed with reagents of the commercial RT-PCR assay, such as  
178 primers and probes for specifically detecting three target genes of the virus [envelope  
179 protein (E) gene, RNA-dependent RNA polymerase (RdRP) gene, and nucleocapsid  
180 protein (N) gene] (20), exogenous internal control, and Real-time One-step Enzyme in an  
181 automated liquid handling workstation (STARlet, Seegene Inc.) to maintain accuracy and  
182 prevent human errors. After that, RT-PCR reactions were performed in a CFX96 real-time  
183 PCR cycler (Bio-Rad, Hercules, CA, USA) as recommended by the manufacturer for  
184 detecting SARS-CoV-2.

185           The nucleic acids extracted from the specimens of the study subjects were also  
186 applied to simultaneously detect respiratory pathogens using commercially available  
187 multiplex real-time PCR assays (Allplex<sup>TM</sup> Respiratory Panel 1, 2, and 3 assay for viruses  
188 and Allplex<sup>TM</sup> PneumoBacter assay for atypical bacteria, Seegene Inc.). The respiratory  
189 viruses detected in this study were influenza A and B (Flu A and Flu B), respiratory  
190 syncytial virus A and B (RSV), adenovirus (Adv), metapneumovirus (MPV), enterovirus  
191 (HEV), parainfluenza viruses 1, 2, 3, and 4 (PIV 1, 2, 3, and 4), bocavirus 1/2/3/4 (HBoV),  
192 rhinovirus (HRV), and other coronaviruses (229E, NL63, and OC43). Atypical bacteria  
193 such as *M. pneumoniae*, *C. pneumoniae*, *L. pneumophila*, and *Bordetella pertussis* were  
194 simultaneously detected with the respiratory viruses. Interpretation for positive and  
195 negative detection of respiratory pathogens by RT-PCR was determined as  
196 recommended by the manufacturer of the multiplex assays.

197

198 **Statistical Analysis**

199 The statistical significance of the difference in detection rates of respiratory  
200 pathogens was analyzed using the Chi-square test or Fisher's exact test. The mean value  
201 comparison of age and Ct values among the study subjects was evaluated using the  
202 Mann–Whitney test. Statistical analysis was conducted using GraphPad Prism software  
203 (Version 5.0; GraphPad Software, Inc., La Jolla, CA, USA) and GraphPad InStat software  
204 (Version 3.0). P values < 0.05 were considered statistically significant.

205

206 **Ethics statement**

207 We retrospectively analyzed the request forms and RT-PCR assay results of the  
208 study subjects, which were exempted from informed consent. This study was approved  
209 by the Institutional Review Boards of Seegene Medical Foundation (SMF-IRB-2020-003)  
210 and Kyungpook National University Hospital (DGIRB202003001-HE002).

211

212

213

214

215

216

## 217 **Results**

### 218 **Study subject enrollment**

219 A total of 258 study subjects with fever and cough were enrolled in this study. After  
220 retrospectively reviewing the request forms and test results of suspects (N = 20,054)  
221 conducted for screening COVID-19 from February 7 to 23, 2020, we found that 404  
222 patients (2.0%) were confirmed as SARS-CoV-2 positive based on the Allplex 2019-nCoV  
223 assay. Among the positives, patients without personal information (N = 62; 15.3%), such  
224 as age, sex, and region where they live, were excluded. Additionally, patients with no  
225 fever or cough as clinical symptoms (N = 84; 20.8%) were also excluded, and 258  
226 subjects who were SARS-CoV-2 positive and had fever (higher than 37.5°C) and cough  
227 were enrolled.

228 The mean age  $\pm$  standard error of the mean (SEM) of the study subjects was 48.5  
229  $\pm$  0.8 y (standard deviation: 15.4, 95% CI: 46.6–50.4) with a median age of 52.0 y . The  
230 detection rates of SARS-CoV-2 by the age of the study subjects were 1.2% (N = 3) for  
231 those below 20 years of age, 26.4% (N = 68) for those between 20 and 39 y, 46.1% (N =  
232 119) for those between 40 and 59 y, and 26.4% (N = 68) for those aged > 60 y. This  
233 indicates that SARS-CoV-2 was mostly detected at the age of 40–59 y in this study.

234 The ratio of males and females was 41.1% (N = 106) and 58.9 % (N = 152),  
235 respectively. Residence area of the study subjects were predominantly Kyungpook  
236 Province, including Daegu city (N = 241, 93.4%), where the first outbreak of COVID-19  
237 occurred in February, followed by Seoul (N = 6, 2.3%), Chungnam Province (N = 5, 1.9%),

238 and Kangwon Province (N = 3, 1.1%).

239

## 240 **Detection of SARS-CoV-2 by types of specimen**

241 Study subjects (N = 258) were retested for SARS-CoV-2 using the Allplex 2019-  
242 nCoV assay. The study subjects were classified as positive for SARS-CoV-2 in both  
243 NPS/OPS and sputum (53.9%, N = 139), positive in NPS/OPS but negative in sputum  
244 (2.3%, N = 6), and negative in NPS/OPS but positive in sputum (4.3%, N = 11) (Fig. 1).  
245 Some patients (39.5%, N = 102) were SARS-CoV-2 positive in NPS/OPS, although their  
246 sputum specimens were not submitted because they were not able to expectorate (Fig.  
247 1). Collectively, when the NPS/OPS specimen was applied without sputum, the positive  
248 rate of SARS-CoV-2 with the Allplex 2019-nCoV assay was 95.7% (N = 247) among the  
249 study subjects (N = 258), suggesting that NPS/OPS would be the most valuable specimen  
250 for molecular diagnosis for detecting SARS-CoV-2, especially in the screening of COVID-  
251 19 (Fig. 1).

252 The study subjects were confirmed to be positive for SARS-CoV-2 when all three  
253 target genes in the Allplex 2019-nCoV assay were positive, as recommended by the  
254 Korea COVID-19 Diagnosis Testing Management Committee (18). Figure 2 shows the  
255 mean cycle threshold (Ct) values of target genes for SARS-CoV-2 in the Allplex 2019-  
256 nCoV assay. The mean Ct values for all study subjects with NPS/OPS (N = 247) were  
257  $20.9 \pm 0.3$  (95% CI: 20.2–21.6) for the E gene,  $22.3 \pm 0.3$  (95% CI: 21.6–22.9) for the  
258 RdRP gene, and  $23.6 \pm 0.3$  (95% CI: 22.8–24.3) for the N gene. In sputum (N = 150), the

259 mean Ct values for E, RdRP, and N genes were  $21.9 \pm 0.4$  (95% CI: 21.1–22.9),  $23.3 \pm$   
260  $0.4$  (95% CI: 22.4–24.2), and  $25.1 \pm 0.4$  (95% CI: 24.3–26.0), respectively. The Ct value  
261 for the E gene came first, RdRP gene second, and N gene third in the Allplex 2019-nCoV  
262 assay applied in this study, and the differences (delta) of the mean Ct values for E, RdRP,  
263 and N genes between NPS/OPS and sputum were 1.0, 1.0, and 1.5, respectively. The  
264 mean Ct values for the E gene and RdRP gene detected in NPS/OPS were not  
265 significantly different from those in sputum ( $P \geq 0.072$ ), but the mean Ct values for the  
266 N gene between NPS/OPS and sputum were significantly different ( $P = 0.0055$ ) (Fig. 2  
267 A). The N gene in sputum was detected significantly later than that in NPS/OPS when the  
268 Allplex 2019-nCoV assay was applied in the same patient.

269 For the study subjects who were SARS-CoV-2 positive in both NPS/OPS and  
270 sputum (53.9%,  $N = 139$ ) (Fig. 1), the mean Ct values for the E, RdRP, and N genes in  
271 NPS/OPS were not significantly different ( $21.4 \pm 0.5$ ,  $22.8 \pm 0.5$ , and  $24.1 \pm 0.5$ ,  
272 respectively) from those ( $21.2 \pm 0.4$ ,  $22.6 \pm 0.4$ , and  $24.5 \pm 0.4$ , respectively) in sputum  
273 ( $P < 0.0001$ ) (Fig. 2 B). However, as shown in Figure 2 C, the mean Ct values ( $23.2 \pm 2.8$ ,  
274  $24.9 \pm 2.6$ , and  $26.0 \pm 2.8$ , respectively) for the E, RdRP, and N genes in the study  
275 subjects who were SARS-CoV-2 positive in NPS/OPS but negative in sputum (2.3%,  $N =$   
276  $6$ ) were significantly lower than those ( $31.7 \pm 1.3$ ,  $22.6 \pm 1.3$ , and  $24.5 \pm 1.2$ , respectively)  
277 who were SARS-CoV-2 positive in sputum but negative in NPS/OPS (4.3%,  $N = 11$ ) ( $P \leq$   
278  $0.0145$ ). The Ct values and viral load of SARS-CoV-2 are inversely proportional; therefore,  
279 the viral loads of SARS-CoV-2 in sputum were significantly lower than those in NPS/OPS.

280 The viral loads of SARS-CoV-2 may influence the difference in the detection rates of the  
281 virus between NPS/OPS and sputum.

282 The patients in whom NPS/OPS specimens were positive although sputum was  
283 not submitted (39.5%, N = 102) (Fig. 1), the mean Ct values ( $20.0 \pm 0.5$ ,  $21.4 \pm 0.5$ , and  
284  $22.6 \pm 0.5$ , respectively) for E, RdRP, and N genes in NPS/OPS specimen (Fig. 2 D) were  
285 significantly lower than those of other study subjects confirmed as SARS-CoV-2 positive  
286 with the same specimen as shown in Figure 2 B and C ( $P \leq 0.0407$ ). Interestingly,  
287 although the patients were not able to expectorate sputum, the viral loads of SARS-CoV-  
288 2 in the NPS/OPS specimen were higher than that of patients who were able to  
289 expectorate sputum.

290

### 291 **Coinfection with Respiratory Pathogens in COVID-19**

292 Coinfection rates with respiratory viruses and atypical bacteria among the study  
293 subjects (N = 258) were 8.5% (N = 22) and 1.2% (N = 3), respectively, which were  
294 significantly different ( $P = 0.0001$ ) (Table 1). Of the respiratory virus coinfection cases (N  
295 = 22), 20 cases (90.9%) of SARS-CoV-2 positive were coinfecting with a single respiratory  
296 virus and two cases (0.8%) (MPV/Adv and HRV/HBoV) were coinfecting with two viruses.  
297 Respiratory viruses in single viral coinfection cases with SARS-CoV-2 were as follows:  
298 non-SARS-CoV-2 coronaviruses [N = 5, 1.9%; 229E (N = 3), NL63 (N = 1), and OC43 (N  
299 = 1)], HRV (N = 4, 1.6%), MPV (N = 3, 1.2%), Flu A (N = 3, 1.2%), RSV (N = 3, 1.2%),

300 and Adv (N = 2, 0.8%).

301           Among the respiratory virus coinfections (N = 22), 59.1% (N = 13) were detected  
302 in both NPS/OPS and sputum. Flu A, HRV, and MPV/Adv were detected only in NPS/OPS,  
303 and RSV, Adv, and non-SARS-CoV-2 coronaviruses were detected only in sputum (Table  
304 1). Notably, four cases of coinfection (two patients with Flu A and two with HRV) provided  
305 only NPS/OPS specimens without sputum (Table 1). The data in this study suggest that  
306 both types of specimens should be employed for detecting coinfections with respiratory  
307 pathogens in COVID-19.

308           All cases of respiratory bacterial coinfection (N = 3; male:female = 2:1) were *M.*  
309 *pneumoniae* detected in both NPS/OPS and sputum specimens without any other atypical  
310 bacteria detected in this study (Table 1). Additionally, no mixed coinfection of viruses and  
311 bacteria among the study subjects was observed.

312           The ratio of males to females in the coinfection cases was 4:6 (Table 1), but no  
313 difference in coinfection by sex was observed ( $P > 0.05$ ), suggesting that both men and  
314 women confirmed that COVID-19 would be susceptible to respiratory pathogens at the  
315 same level.

316           The mean age of coinfection cases (N = 25, 9.7%) with respiratory pathogens  
317 (both virus and bacteria) was  $38.4 \pm 3.3$  y, which was significantly lesser than the mean  
318 age ( $49.6 \pm 1.0$ ) of patients without coinfections ( $P = 0.0009$ ). The mean ages for viral (N  
319 = 22) and bacteria (N = 3) coinfection cases were  $39.2 \pm 3.6$  y and  $32.0 \pm 6.0$  y,  
320 respectively, which were not statistically significant ( $P = 0.4841$ ) (Table 1). Most of the



321 coinfection cases resided in Kyungpook Province, except two cases (coinfections of Adv  
322 and HRV in Kyunggi Province and Seoul, respectively) (Table 1).

323 Figure 3 shows the age distribution of coinfection cases (N = 25) with respiratory  
324 pathogens among the study subjects (N = 258). The rates of coinfections in the age  
325 groups of < 20 years old, between 20 and 39, between 40 and 59, and > 60 were 0.4%  
326 (N = 1), 4.3% (N = 11), 4.3% (N = 11), and 0.8% (N = 2), respectively. Coinfections with  
327 Flu A were detected at ages below 20 y (N = 1) and between 40 and 59 y (N = 2). At age  
328 > 60 y, both RSV and other coronaviruses were coinfecting. Two cases (0.8%) of double  
329 viral coinfections were found at ages between 20 and 39 y (HRV/HBoV) and between 40  
330 and 59 y (MPV/Adv), respectively. All other coinfection cases (7.0%, N = 18) with virus  
331 and *M. pneumoniae* were detected between 20 and 59 years of age.

332 Ct values of target genes (E, RdRP, and N) specific to SARS-CoV-2 in coinfection  
333 cases with respiratory pathogens were not significantly different from those in non-  
334 coinfection cases in the patients of COVID-19 when applying the Allplex 2019-nCoV  
335 assay, regardless of the type of respiratory specimen ( $P \geq 0.2771$ ).

336

337

338

339

## 340 Discussion

341 In Korea, both NPS and OPS were placed in a UTM tube after collection from  
342 suspects of COVID-19 for screening (9). The UTM tubes were transported for COVID-19  
343 testing to the laboratory immediately after collection, with or without sputum samples. No  
344 other upper or lower respiratory tract samples were transported and tested. Among the  
345 suspects (N = 20,054) tested from February 9 to 23, 2020, during the first outbreak in  
346 Korea, the positive rate of SRAS-CoV-2 was 2.0% (N = 404) using the RT-PCR assay,  
347 which was lower than the finding (9.5%; N = 116) in a previous study, when tested for  
348 patients in the USA (N = 1,217) enrolled from March 3 to 25, 2020 (21). From the positive  
349 (N = 404), patients (N=258) with clinical symptoms (fever and cough) were enrolled as  
350 study subjects for this study.

351 Among the study subjects (N = 258), 95.7% (N = 247) were confirmed to be  
352 positive for SARS-CoV-2 in the RT-PCR assay by sampling NPS/OPS, regardless of the  
353 collection of sputum (Fig. 1). Additionally, based on a comparison of the mean Ct values  
354 for the genes specific to SARS-CoV-2, higher viral loads of SARS-CoV-2 were observed  
355 in NPS/OPS than in sputum (Fig. 2), which would support the excellent detection rates of  
356 SARS-CoV-2 in NPS/OPS (Fig. 1). This suggests that NPS/OPS would be the most  
357 valuable for diagnosing SARS-CoV-2 in molecular diagnosis assays, and it would not be  
358 necessary to enforce sampling sputum specimens, especially when the patients were not  
359 able to expectorate. However, in previous studies, sputum specimens were considered a  
360 better choice than nasal samples for the molecular detection of SARS-CoV-2. Pan et al.

361 (6) measured the viral loads of SARS-CoV-2 from two COVID-19 patients at the early  
362 stage of onset of symptoms in throat, sputum, urine, and stool. They found that the viral  
363 loads were higher in sputum samples than in throat samples, especially in the early days  
364 after onset. Wang et al. (5) compared the detection rates of SARS-CoV-2 among multiple  
365 types of specimens collected from patients with COVID-19, bronchoalveolar lavage fluid  
366 showed 93% positive rate as the highest, followed by sputum (72%), nasal swab (63%),  
367 and pharyngeal swabs (32%). Collectively, based on the literature published, for detecting  
368 SARS-CoV-2 in the patients, the best clinical specimen recommended was  
369 bronchoalveolar lavage fluid, and sputum was the second with strong recommendation,  
370 whereas pharyngeal swabs were in moderate (22, 23). In contrast, our data support that  
371 pharyngeal swab samples would be better than sputum in detecting SARS-CoV-2 among  
372 the study subjects who underwent COVID-19 screening. A consistent finding with the  
373 current study was also observed in a case study of two Korean patients, reporting that  
374 viral loads of upper respiratory specimens (placing both NPS and OPS in the same tube)  
375 were detected as similar to or sometimes higher than those in sputum using RT-PCR (24).

376 Coinfection rate in patients with COVID-19 (N = 258) with respiratory pathogens  
377 was 9.7% (N = 25) in the current study (Table 1 and Figure 3): 8.5% (N = 22) of viral and  
378 1.2% (N = 3) of atypical bacterial coinfections. The rate of viral coinfection has been  
379 previously reported to range from 2.0% – 19.8% in different countries (21, 25-27). The  
380 coinfection rate with respiratory viruses was 2.0% (N = 39) among 1,996 patients with  
381 COVID-19 hospitalized in New York City (25). Tested at a hospital in Shenzhen, China,  
382 six (3.2%) of 92 COVID-19 patients hospitalized were viral coinfection cases (26). Another

383 study conducted in Wuhan, China, reported that among patients with COVID-19 (N = 104),  
384 5.8% (N = 6) had coinfections with non-SARS-CoV-2 coronaviruses (2.9%, N = 3),  
385 influenza A (2.9%, N = 3), and rhinovirus (1.9%, N = 2) (27). In the study by Kim et al. (21)  
386 with patients in California, USA, 19.8% (N = 23) of SARS-CoV-2 positive patients (N =  
387 116) were positive for other respiratory pathogens. As the first report in Korea  
388 representing the suspect group of COVID-19, especially from the first outbreak area in  
389 February 2020, 8.5% of viral coinfections were found in this study, which is comparable  
390 with previous reports.

391         Among the coinfections (N=25) by respiratory virus (N = 22) and the atypical  
392 bacteria *M. pneumoniae* (N = 3), most cases were detected in both the NPS/OPS and  
393 sputum specimens (64.0%, N=16), but some were in either NPS/OPS (20.0%, N=5) or  
394 sputum (16.0%, N=4) (Table 1). This suggests that both upper and lower respiratory tract  
395 specimens would be recommended to monitor the coinfection with respiratory pathogens  
396 in COVID-19. This is consistent with a previous report by Zhu et al. (14), who suggested  
397 that for detecting coinfections with respiratory pathogens in COVID-19, both upper and  
398 lower respiratory tract specimens should be collected and considered to test while  
399 diagnosing and treating COVID-19.

400         Based on a meta-analysis by Lansbury et al. (12) with the previously reported  
401 studies regarding types of co-infected respiratory viruses in patients with SARS-CoV-2,  
402 the most common co-infecting virus was RSV, followed by Flu A, HRV, PIV, and other  
403 coronaviruses. A study in China, which was not included in the meta-analysis, consistently

404 reported that RSV was most commonly detected among the coinfection viruses in COVID-  
405 19 patients diagnosed between January 19 and February 26, 2020 (15). However, in the  
406 USA, Kim et al. (21) and Richardson et al. (25) detected rhinovirus/enterovirus as the  
407 most common coinfection agent in their study, followed by RSV among the study subjects  
408 enrolled in March 2020. In this study with Korean study subjects enrolled in February  
409 2020, the most common respiratory virus as the coinfection agent was HRV [1.9 %, N =  
410 5; one double viral coinfection with HBoV (HRV/HBoV) and four single viral coinfection  
411 cases in SARS-CoV 2 positive] (Table 1). Five cases of single viral coinfections by non-  
412 SARS-CoV-2 coronaviruses (three cases of 229E, one case of NL63, and one case of  
413 OC43) were also observed (Table 1).

414 SARS-CoV-2 and influenza coinfection was relatively rare in three patients (1.2%)  
415 among the study subjects (N = 258) (Table 1). This finding is also consistent with previous  
416 studies, such as 0.54% in Turkey (13), 0.9% (21) and 2.4% (25) in the USA, and from  
417 1.2%–4.3% in China (14, 15, 27, 28).

418 Among the atypical bacteria tested in this study, only *M. pneumoniae* was  
419 detected at the level of 1.2% (N = 3) of the study subjects (N = 258) (Table 1). In some  
420 other studies, however, *C. pneumoniae*, another atypical bacterium, was nominated as  
421 the coinfection agent in patients with COVID-19 in addition to *M. pneumoniae* (14, 15, 25).  
422 The coinfection rates in the above studies for *M. pneumoniae* and *C. pneumoniae* ranged  
423 from 1.6%–4.8% and 2.5%–5.2%, respectively. Lansbury et al. (12) emphasized, in their  
424 meta-analysis study, that *M. pneumoniae* was the most common bacteria detected in

425 patients with COVID-19 having coinfections with respiratory bacterial pathogens, followed  
426 by *P. aeruginosa*, *H. influenza*, *Klebsiella pneumoniae*, and *Chlamydomphila* spp.,  
427 suggesting that in addition to coinfection by atypical bacteria, other respiratory bacteria  
428 were also the candidates as co-infecting agents in COVID-19.

429 Unlike Kim et al. (21), who reported no difference in age between coinfection and  
430 SARS-CoV-2 only (non-coinfection), the mean ages between them were significantly  
431 different in this study ( $38.4 \pm 3.3$  y vs.  $49.6 \pm 1.0$  y, respectively;  $P = 0.0009$ ). This  
432 suggested that young ages were more susceptible to coinfection with respiratory  
433 pathogens in this study.

434 The viral loads of SARS-CoV-2 between the patients with coinfection and SARS-  
435 CoV-2 only infection were not significantly different as Ct values for the target genes (E,  
436 RdRP, and N) were statistically the same between them when the Allplex 2019-nCoV  
437 assay was applied ( $P > 0.05$ ). This suggests that the viral load of SARS-CoV-2 is not  
438 responsible to cause coinfection with respiratory pathogens.

439 The current study has a few limitations. The effect of coinfection on the treatment  
440 outcomes of COVID-19 patients enrolled in this study is unavailable. The study subjects  
441 in this study were retrospectively enrolled during the process of screening COVID-19 in  
442 the region of the first outbreak in Korea. Thus, the scope of this study was to investigate  
443 the coinfection rates of respiratory pathogens among patients with COVID-19, not  
444 hospitalized, but diagnosed as positive during the screening process for SARS-CoV-2.  
445 Additionally, the results of the study cannot represent the coinfection rates for the winter

446 when respiratory pathogens such as influenza are dominant. The study subjects were  
447 only enrolled in February; therefore, investigating the coinfection rates with respiratory  
448 pathogens would be interesting during the whole winter season, especially from  
449 November to March in Korea.

450 In summary, the upper respiratory tract specimen (NPS/UPS) provided excellent  
451 detection of SARS-CoV-2 without lower respiratory specimens (sputum) in the RT-PCR  
452 assay. However, detection of coinfections with respiratory pathogens in COVID-19  
453 required both upper and lower respiratory specimens. Coinfection rates in patients with  
454 COVID-19 (N = 258) with respiratory pathogens were 9.7% (N = 25) with mostly virus  
455 (8.5%, N = 22) and an atypical bacterium, *M. pneumoniae* (1.2%, N = 3). The most  
456 common respiratory virus detected as a coinfecting agent was HRV, followed by non-  
457 SARS-CoV-2 coronaviruses, HRV, MPV, Flu A, RSV, and Adv. As a conclusion,  
458 simultaneous detection of respiratory pathogens and SARS-CoV-2 by molecular  
459 diagnosis assays would be necessary for identifying the causative agents causing  
460 coinfection, especially during the COVID-19 pandemic.

461

462

463

464

465

466 **Acknowledgements**

467           The authors appreciate Prof. Doosu Jeon at Busan National University Yangsan  
468 Hospital for his critical review and comments. This research was funded in part by the  
469 KOICA IBS program (2018-0119). The current study was supported by the Korea Disease  
470 Control and Prevention Agency (KDCA) by COVID-19 Testing Service contracted to the  
471 Seegene Medical Foundation.

472

473 **Declaration of Interest Statement**

474 All authors have no potential conflicts of interest to disclose for this study.

475

476

477

478

479

480

481

482

483



## 484 **References**

- 485 1. World Health Organization. 2020. Coronavirus disease (COVID-19) Weekly  
486 Epidemiological Update; 25 October 2020.  
487 [https://www.who.int/publications/m/item/weekly-epidemiological-update---27-](https://www.who.int/publications/m/item/weekly-epidemiological-update---27-october-2020)  
488 [october-2020](https://www.who.int/publications/m/item/weekly-epidemiological-update---27-october-2020). Accessed on Oct 30 2020
- 489 2. Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, Park JH, Na HK, Oh MD. 2020.  
490 The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from  
491 Wuhan, China: Implication for Infection Prevention and Control Measures. J  
492 Korean Med Sci 35:e61.
- 493 3. Kim YJ, Sung H, Ki CS, Hur M. 2020. COVID-19 Testing in South Korea: Current  
494 Status and the Need for Faster Diagnostics. Ann Lab Med 40:349-350.
- 495 4. Loeffelholz MJ, Tang YW. 2020. Laboratory diagnosis of emerging human  
496 coronavirus infections - the state of the art. Emerg Microbes Infect 9:747-756.
- 497 5. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. 2020. Detection of SARS-CoV-  
498 2 in Different Types of Clinical Specimens. JAMA 323:1843-1844.
- 499 6. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. 2020. Viral load of SARS-CoV-2 in  
500 clinical samples. The Lancet Infectious Diseases 20:411-412.
- 501 7. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J,  
502 Guo Q, Song T, He J, Yen H-L, Peiris M, Wu J. 2020. SARS-CoV-2 Viral Load in  
503 Upper Respiratory Specimens of Infected Patients. New England Journal of  
504 Medicine 382:1177-1179.
- 505 8. Centers for Disease Control and Prevention. 2020. Coronavirus Disease 2019


- 506 (COVID-19). [https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-](https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html#specimen)  
507 [specimens.html#specimen](https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html#specimen). Accessed on Oct 30 2020
- 508 9. Sung H, Roh KH, Hong KH, Seong MW, Ryoo N, Kim HS, Lee J, Kim SY, Ryu SW,  
509 Kim MN, Han MG, Lee SW, Lee H, Yoo CK. 2020. COVID-19 Molecular Testing in  
510 Korea: Practical Essentials and Answers From Experts Based on Experiences of  
511 Emergency Use Authorization Assays. *Ann Lab Med* 40:439-447.
- 512 10. Chen X, Liao B, Cheng L, Peng X, Xu X, Li Y, Hu T, Li J, Zhou X, Ren B. 2020. The  
513 microbial coinfection in COVID-19. *Appl Microbiol Biotechnol* 104:7777-7785.
- 514 11. Lai CC, Wang CY, Hsueh PR. 2020. Co-infections among patients with COVID-19:  
515 The need for combination therapy with non-anti-SARS-CoV-2 agents? *J Microbiol*  
516 *Immunol Infect* 53:505-512.
- 517 12. Lansbury L, Lim B, Baskaran V, Lim WS. 2020. Co-infections in people with  
518 COVID-19: a systematic review and meta-analysis. *J Infect* 81:266-275.
- 519 13. Ozaras R, Cirpin R, Duran A, Duman H, Arslan O, Bakcan Y, Kaya M, Mutlu H,  
520 Isayeva L, Kebanli F, Deger BA, Bekeshev E, Kaya F, Bilir S. 2020. Influenza and  
521 COVID-19 coinfection: Report of six cases and review of the literature. *J Med Virol*  
522 doi:10.1002/jmv.26125.
- 523 14. Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, Zhu F, Zhu B, Cui L. 2020. Co-infection  
524 with respiratory pathogens among COVID-2019 cases. *Virus Res* 285:198005.
- 525 15. Ma L, Wang W, Le Grange JM, Wang X, Du S, Li C, Wei J, Zhang JN. 2020.  
526 Coinfection of SARS-CoV-2 and Other Respiratory Pathogens. *Infect Drug Resist*  
527 13:3045-3053.

- 528 16. Yang H, Lu S. 2020. COVID-19 and Tuberculosis. *J Transl Int Med* 8:59-65.
- 529 17. Bandyopadhyay A, Palepu S, Bandyopadhyay K, Handu S. 2020. COVID-19 and  
530 tuberculosis co-infection: a neglected paradigm. *Monaldi Arch Chest Dis* 90:518-  
531 522.
- 532 18. Hong KH, Lee SW, Kim TS, Huh HJ, Lee J, Kim SY, Park JS, Kim GJ, Sung H,  
533 Roh KH, Kim JS, Kim HS, Lee ST, Seong MW, Ryoo N, Lee H, Kwon KC, Yoo CK.  
534 2020. Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-  
535 19) in Korea. *Ann Lab Med* 40:351-360.
- 536 19. World Health Organization. 2020. Laboratory testing for 2019 novel coronavirus  
537 (2019-nCoV) in suspected human cases -Interim guidance.  
538 [https://www.who.int/publications/i/item/laboratory-testing-of-2019-novel-](https://www.who.int/publications/i/item/laboratory-testing-of-2019-novel-coronavirus-(-2019-ncov)-in-suspected-human-cases-interim-guidance-17-january-2020)  
539 [coronavirus-\(-2019-ncov\)-in-suspected-human-cases-interim-guidance-17-](https://www.who.int/publications/i/item/laboratory-testing-of-2019-novel-coronavirus-(-2019-ncov)-in-suspected-human-cases-interim-guidance-17-january-2020)  
540 [january-2020](https://www.who.int/publications/i/item/laboratory-testing-of-2019-novel-coronavirus-(-2019-ncov)-in-suspected-human-cases-interim-guidance-17-january-2020). Accessed on Oct 13 2020
- 541 20. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T,  
542 Brunink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B,  
543 van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M,  
544 Goossens H, Reusken C, Koopmans MP, Drosten C. 2020. Detection of 2019  
545 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 25:23-30.
- 546 21. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. 2020. Rates of Co-infection Between  
547 SARS-CoV-2 and Other Respiratory Pathogens. *JAMA* 323:2085-2086.
- 548 22. Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, Singh KP, Chaicumpa W,  
549 Bonilla-Aldana DK, Rodriguez-Morales AJ. 2020. Coronavirus Disease 2019-

- 550 COVID-19. Clin Microbiol Rev 33:1-48.
- 551 23. Feng W, Newbigging AM, Le C, Pang B, Peng H, Cao Y, Wu J, Abbas G, Song J,  
552 Wang DB, Cui M, Tao J, Tyrrell DL, Zhang XE, Zhang H, Le XC. 2020. Molecular  
553 Diagnosis of COVID-19: Challenges and Research Needs. Anal Chem 92:10196-  
554 10209.
- 555 24. Kim JY, Ko JH, Kim Y, Kim YJ, Kim JM, Chung YS, Kim HM, Han MG, Kim SY,  
556 Chin BS. 2020. Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients  
557 in Korea. J Korean Med Sci 35:e86.
- 558 25. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW,  
559 Consortium atNC-R. 2020. Presenting Characteristics, Comorbidities, and  
560 Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City  
561 Area. JAMA 323:2052-2059.
- 562 26. Lin D, Liu L, Zhang M, Hu Y, Yang Q, Guo J, Guo Y, Dai Y, Xu Y, Cai Y, Chen X,  
563 Zhang Z, Huang K. 2020. Co-infections of SARS-CoV-2 with multiple common  
564 respiratory pathogens in infected patients. Sci China Life Sci 63:606-609.
- 565 27. Wang M, Wu Q, Xu W, Qiao B, Wang J, Zheng H, Jiang S, Mei J, Wu Z, Deng Y,  
566 Zhou F, Wu W, Zhang Y, Lv Z, Huang J, Guo X, Feng L, Xia Z, Li D, Xu Z, Liu T,  
567 Zhang P, Tong Y, Li Y. 2020. Clinical diagnosis of 8274 samples with 2019-novel  
568 coronavirus in Wuhan. medRxiv doi:10.1101/2020.02.12.20022327.
- 569 28. Ding Q, Lu P, Fan Y, Xia Y, Liu M. 2020. The clinical characteristics of pneumonia  
570 patients coinfecting with 2019 novel coronavirus and influenza virus in Wuhan,  
571 China. J Med Virol doi:10.1002/jmv.25781.

572 **Figure 1.** Classification of the study subjects by different types of respiratory specimen.

573



574

575 Upper (NPS/OPS) and lower (sputum) respiratory specimens of the study subjects were  
576 retested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using Allplex  
577 2019-nCoV Assay. The study subjects (N=258) were confirmed to be positive for SARS-  
578 CoV-2 in both NPS/OPS and sputum at 53.9% (N = 139), positive in NPS/OPS but  
579 negative in sputum at 2.3% (N = 6), negative in NPS/OPS but positive in sputum at 4.3%  
580 (N = 11). Some (39.5%, N = 102) were positive in NPS/OPS when sputum samples were  
581 not submitted.


582

583 NPS: Nasopharyngeal swab, OPS: Oropharyngeal swab, NS: Specimen were not  
584 submitted for COVID-19 (Coronavirus disease 2019) testing, Pos: Positive, Neg: Negative

585

586 **Figure 2.** Ct values of E gene, RdRP gene, and E gene in Allplex 2019-nCoV assay for  
587 SARS-CoV-2 extracted from NPS/OPS and sputum collected from the study group  
588 (N=258).

589



590

591 A. Ct values of E gene, RdRP gene and N gene detected in NPS/OPS (N=247) and  
592 sputum (N=150) among all of the study subjects (N=258). B. Ct values among the study  
593 subjects (N=139) classified as positive for SARS-CoV-2 in both NPS/OPS and sputum.  
594 C. Ct values among the study subjects (N=6) classified as positive for SARS-CoV-2 in  
595 NPS/OPS but negative in sputum (NPS/OPS + but sputum -) and the subjects (N=11) as

596 negative for SARS-CoV-2 in NPS/OPS but positive in sputum (NPS/OPS – but sputum  
597 +). D. Ct values among the study subjects (N=102) classified as positive for SARS-CoV-  
598 2 in NPS/OPS even though sputum specimen were not submitted.

599

600 Ct: Cycle threshold, SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2,  
601 NPS: Nasopharyngeal swab, OPS: Oropharyngeal swab, E: Envelope protein gene,  
602 RdRP: RNA-dependent RNA polymerase gene, and N: Nucleocapsid protein gene

603 \* indicates significantly different; differences in Ct values of E gene, RdRP gene, and N  
604 gene between SARS-CoV-2 positive in NPS/OPS but negative in sputum (N = 6) and  
605 negative in NPS/OPS but positive in sputum (N = 11) were 8.5, 7.9, and 7.4, respectively,  
606 which were significantly different ( $P \leq 0.0145$ ).

607

608

609

610

611


612

613

614 **Figure 3**

615 Distribution of respiratory pathogens by different ages in the coinfection cases (N = 25) in  
616 COVID-19 among the study subjects (N = 258).

617



618

619 The numbers of coinfection cases based on the age distributions were 1 (0.4%), 11 (4.3%),  
620 11 (4.3%), and 2 (0.8%) for ages below 20, between 20 and 39, between 40 and 59, and  
621 above 60, respectively.

622

623 COVID-19: Coronavirus disease 2019

624 Flu A; Influenza A, RSV; Respiratory syncytial virus, Adv; Adenovirus, MPV;



625 Metapneumovirus, HRV; Rhinovirus, Other CoronaV; Coronavirus such as 229E, NL63,  
626 and OC43, and *M. pneumoniae*; *Mycoplasma pneumoniae*,

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642 **Table 1.**

643 Study subjects (N=258) coinfecting with respiratory pathogens in COVID-19.

Patients Coinfected with Respiratory Pathogens	No of Patients Coinfected (%)	M:F	Mean Age (SEM)	Region of Residency (No. of Patients)	Classification of the Coinfections by Types of Specimen (N=25)			
					No. (%) of SARS-CoV-2 Positive in:			
					NPS/OPS	Sputum	Both	
Flu A	3 (1.2)	1:2	30.3 (14.7)	KP (3)	2*	-	1	
RSV	3 (1.2)	0:3	47.0 (15.5)	KP (3)	-	2	1	
Adv	2 (0.8)	2:0	29.0 (8.0)	KP (1), KG (1)	-	1	1	
MPV	3 (1.2)	1:2	40.3 (8.0)	KP (3)	-	-	3	
Virus (N=22, 8.5%)	HRV	4 (1.6)	1:3	43.8 (7.7)	KP (3), Seoul (1)	2*	-	2
	Non-SARS-CoV-2 Coronavirus	5 (1.9)	3:2	39.8 (6.9)	KP (5)	-	1	4
	MPV/Adv	1 (0.4)	0:1	53	KP (1)	1	-	-
	HRV/HBoV	1 (0.4)	0:1	25	KP (1)	-	-	1
	Bacteria (N=3, 1.2%)	<i>M. pneumoniae</i>	3 (1.2)	2:1	32.0 (6.0)	KP (3)	-	-
Total (N=25, 9.7%)		25	10:15	38.4 (3.3)		5 (20.0)	4 (16.0)	16 (64.0)

644

645 COVID-19: Coronavirus disease 2019

646 Flu A; Influenza A, RSV; Respiratory syncytial virus, Adv; Adenovirus, MPV;  
 647 Metapneumovirus, HRV; Rhinovirus, Non-SARS-CoV-2 Coronavirus (Coronavirus 229E,  
 648 NL63, and OC43), *M. pneumoniae*; *Mycoplasma pneumoniae*, KP; Kyungpook Province,  
 649 and KG; Kyunggi Province. SEM: Standard Error of Mean

650 \* NPS/OPS specimen were only submitted without sputum.

651